Logo

If at First You Don't Succeed …

Nov 01, 2010

Samuel Waksal, the former CEO of ImClone who was made famous when he went to prison for an insider trading scheme involving home crafts maven Martha Stewart, is out and ready to try again, reports the New York Times' Andrew Pollack. Less than two years after being released from prison, Waksal has started a new biotech company called Kadmon Pharmaceuticals, which he says will have "significant revenues," five Phase 3 products, and a couple of Phase 2 products by next year. Kadmon is focusing on cancer, infections, and autoimmune diseases, Pollack says. The company has already licensed an experimental hepatitis C drug from Valeant Pharmaceuticals International, and has acquired Three Rivers Pharmaceuticals, which specializes in hepatitis drugs, according to Pollack.

Breaking News
The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.